|Title||Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial|
|Publication Type||Journal Article|
|Year of Publication||2011|
|Authors||Woodward, M, Patel, A, Zoungas, S, Liu, L, Pan, C, Poulter, N, Januszewicz, A, Tandon, N, Joshi, P, Heller, SR, Neal, B, Chalmers, J|
|ISBN Number||1935-5548 (Electronic)0149-5992 (Linking)|
OBJECTIVE: Participants in ADVANCE were drawn from many countries. We examined whether the effects of intensive glycemic control on major outcomes in ADVANCE differ between participants from Asia, established market economies (EMEs), and eastern Europe. RESEARCH DESIGN AND METHODS: ADVANCE was a clinical trial of 11,140 patients with type 2 diabetes, lasting a median of 5 years. Demographic and clinical characteristics were compared across regions using generalized linear and mixed models. Effects on outcomes of the gliclazide modified release-based intensive glucose control regimen, targeting an HbA(lc) of
/= 0.23) between regions for any outcome, including mortality, vascular end points, and severe hypoglycemic episodes. CONCLUSIONS: Irrespective of absolute risk, the effects of intensive glycemic control with the gliclazide MR-based regimen used in ADVANCE were similar across Asia, EMEs, and eastern Europe. This regimen can safely be recommended for patients with type 2 diabetes in all of these regions.
Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial